{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:53:54Z","timestamp":1768280034846,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Carbapenem\u2010resistant\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    <\/jats:styled-content>\n                    (CRAB) are difficult\u2010to\u2010treat pathogens that primarily cause health care\u2010associated infections. Sulbactam\/durlobactam (SUL\/DUR) is a novel antibiotic combination that is uniquely formulated to target CRAB isolates. However, investigations of SUL\/DUR's pharmacokinetics in obese patients are limited. Here, we report on the successful treatment of CRAB bacteremia in a patient with acute renal failure and severe obesity (weight 273\u2009kg, body mass index 103\u2009kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) with SUL\/DUR and meropenem combination therapy. The patient had a calculated creatinine clearance of 25\u2009mL\/min and received therapy with intravenous SUL\/DUR 1\u2009g\/1\u2009g every 8\u2009h over 3\u2009h in combination with intravenous meropenem 500\u2009mg every 8\u2009h to complete 14\u2009days of therapy. Pharmacokinetic analysis revealed target attainment with prolonged half\u2010life (\n                    <jats:italic>T<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    ) and volume of distribution (Vd) of 35.3\u2009h and 81.3\u2009L for sulbactam and 30.5\u2009h and 169.1\u2009L for durlobactam, respectively. Susceptibility testing using the broth disk elution test did not show synergy between SUL\/DUR and meropenem. No adverse effects were observed, and the patient achieved clinical cure without recurrence of\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>A.\u2009baumannii<\/jats:italic>\n                    <\/jats:styled-content>\n                    infection.\n                  <\/jats:p>","DOI":"10.1002\/phar.70042","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:08:59Z","timestamp":1752833339000},"page":"522-528","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics of Sulbactam\/Durlobactam in a Patient With Acute Renal Failure, Severe Obesity, and Carbapenem\u2010Resistant\n                    <scp>\n                      <i>Acinetobacter baumannii<\/i>\n                    <\/scp>\n                    Bacteremia: A Case Report"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-3901","authenticated-orcid":false,"given":"Dan","family":"Ilges","sequence":"first","affiliation":[{"name":"Department of Pharmacy Mayo Clinic Arizona  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9359-0930","authenticated-orcid":false,"given":"Yakun","family":"Fu","sequence":"additional","affiliation":[{"name":"Center for Anti\u2010Infective Research &amp; Development Hartford Hospital  Hartford Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8018-4070","authenticated-orcid":false,"given":"Drew T.","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Mayo Clinic Arizona  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3061-2492","authenticated-orcid":false,"given":"John C.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Mayo Clinic Arizona  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7017-3607","authenticated-orcid":false,"given":"Lisa","family":"Speiser","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Mayo Clinic Arizona  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti\u2010Infective Research &amp; Development Hartford Hospital  Hartford Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Centers for Diseases Prevention and Control \u201cCarbapenem\u2010ResistantAcinetobacter baumannii(CRAB): An Urgent Public Health Threat in United States Healthcare Facilities \u201dhttps:\/\/arpsp.cdc.gov\/story\/cra\u2010urgent\u2010public\u2010health\u2010threat."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad094"},{"key":"e_1_2_9_5_1","unstructured":"\u201cXACDURO (Sulbactam for Injection; Durlobactam for Injection)\u201d(La Jolla Pharmaceutical Company 2023 Package Insert)."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2802"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00781\u201022"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2769"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2023"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251313874"},{"key":"e_1_2_9_11_1","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute","year":"2025"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01647\u201022"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2025.124654"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfab036"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1819"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00485\u201024"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab212"},{"key":"e_1_2_9_18_1","unstructured":"\u201cUNASYN (Ampicillin Sodium\/Sulbactam Sodium)\u201d(Pfizer Injectables 2020 Package Insert)."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(23)00184\u20106"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00800\u201023"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469\u20100691.2004.00987.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh080"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(23)00422\u2010X"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01258\u201023"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(23)00423\u20101"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:49:31Z","timestamp":1761068971000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/phar.70042"],"URL":"https:\/\/doi.org\/10.1002\/phar.70042","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"2025-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}